Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
08 Februar 2021 - 11:23PM
Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced the closing of its upsized initial public offering of
27,025,000 shares of its common stock at a public offering price of
$25.00 per share, which includes the full exercise by the
underwriters of their option to purchase 3,525,000 additional
shares of common stock. The aggregate gross proceeds from the
offering, before deducting underwriting discounts and commissions
and other offering expenses payable by Sana, were approximately
$675.6 million. All of the shares of common stock were offered by
Sana. Sana’s common stock is listed on The Nasdaq Global Select
Market under the ticker symbol “SANA.”
Morgan Stanley, Goldman Sachs & Co. LLC,
J.P. Morgan and BofA Securities acted as joint book-running
managers for the offering.
Registration statements relating to the shares
being sold in this offering were filed with the Securities and
Exchange Commission and became effective on February 3, 2021. The
offering was made only by means of a prospectus, copies of which
may be obtained from: Morgan Stanley, Attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by
email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by email at prospectus-eq_fi@jpmorgan.com, or
by telephone at (866) 803-9204; or BofA Securities, NC1-004-03-43,
200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Sana
Sana Biotechnology, Inc. is focused on creating
and delivering engineered cells as medicines for patients. Sana
shares a vision of repairing and controlling genes, replacing
missing or damaged cells, and making its therapies broadly
available to patients. Sana is more than 250 people working
together to create an enduring company that changes how the world
treats disease. Sana has operations in Seattle, Cambridge, and
South San Francisco.
Investor Relations:Nicole
Keithinvestor.relations@sana.com
Media:Morgan Warners, Finsbury Glover
Heringmedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jul 2023 bis Jul 2024